Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW CCO & CMO present at BIO partnering conference in Boston

Chief Commercial Officer, Mr Andy Udell, and Chief Medical Officer, Dr Dana Hilt MD, are conducting meetings and delivering a company presentation at the BIO International Convention (BIO 2025) in Boston, USA
They are engaging with international investors and potential biopharma partners throughout the conference to discuss ACW’s latest advancements and the potential of our lead asset, Xanamem®.

Courier Mail article

The Courier Mail has published an article discussing the XanaMIA Alzheimer’s trial and the potential for Xanamem to become the “holy grail” in the quest to find a treatment for the disease.

Clinical Trials Science Forum webinar recording posted on ACW YouTube channel

ACW’s CMO Dr Dana Hilt and guest A/Prof Michael Woodward from Austin Health lead a highly informative ‘plain English’ presentation and panel discussion that reviews the scope of leading current and potential treatments in development for Alzheimer’s disease & the ongoing significant unmet medical need for effective therapies. Then, Chief Commercial Officer, Andy Udell, outlines what commercialization planning means for a company like Actinogen.

ACW Clinical Trials Science Forum slides

This announcement includes the slide presentation by ACW CMO Dana Hilt, CCO Andy Udell and A/Prof Michael Woodward from Austin Health  in  a webinar on the latest developments in the quest for effective Alzheimer’s treatments and how ACW is preparing for the future commercialization of its novel once-a-day oral medication, Xanamem.

ACW CMO presents Xanamem pTau poster at ADPD25 conference

ACW Chief Medical Officer, Dr Dana Hilt MD is presenting an academic poster at the 19th International Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD™25)  in Vienna, Austria.

The poster details the promising benefits of Xanamem® treatment over 12 weeks in patients with elevated blood pTau181. It also reports that higher levels of blood pTau181 can identify patients with Alzheimer’s disease who have more rapid clinical progression.

Actinogen conducts Type C meeting with FDA regarding depression

Actinogen announces the successful conduct of its scheduled Type C meeting on major depressive disorder (MDD) with the US Food & Drug Administration (FDA).

In a collegial meeting, Actinogen and the FDA reached a common understanding of the additional clinical trials, ancillary clinical pharmacology trials and nonclinical studies required to apply for marketing approval of Xanamem for MDD in the future.